臺大學術典藏 |
2021-07-21T23:21:29Z |
Phase I/Ib clinical trial of sabatolimab, an anti–TIM-3 antibody, alone and in combination with spartalizumab, an anti–PD-1 antibody, in advanced solid tumors
|
Curigliano, Giuseppe; Gelderblom, Hans; Mach, Nicolas; Doi, Toshihiko; Tai, David; Forde, Patrick M.; Sarantopoulos, John; Bedard, Philippe L.; Chia-Chi Lin; Stephen Hodi, F.; Wilgenhof, Sofie; Santoro, Armando; Sabatos-Peyton, Catherine A.; Longmire, Tyler A.; Xyrafas, Alexandros; Sun, Haiying; Gutzwiller, Sabine; Manenti, Luigi; Naing, Aung |